Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
- 21 December 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 22 (1), 85-97
- https://doi.org/10.1016/s1470-2045(20)30536-2
Abstract
No abstract availableFunding Information
- Genentech
- F. Hoffmann-La Roche
This publication has 32 references indexed in Scilit:
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studyThe Lancet Oncology, 2020
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateArchives of Pathology & Laboratory Medicine, 2018
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerThe New England Journal of Medicine, 2017
- HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-upEuropean Journal of Cancer, 2016
- A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancerCancer Medicine, 2016
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialThe Lancet Oncology, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Catheter-Associated Thrombosis in Patients With MalignancyJournal of Clinical Oncology, 2009
- Complications of an implantable venous access device (Port-a-Cath®) during intermittent continuous infusion of chemotherapyEuropean Journal of Cancer, 1996
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987